Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers
who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against …

Cost-effective, efficacious therapeutics are urgently needed to combat the COVID-19
pandemic. In this study, we used camelid immunization and proteomics to identify a large …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

To investigate the evolution of SARS-CoV-2 in the immune population, we co-incubated
authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The …

To investigate the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in the immune population, we coincupi bated the authentic virus with a highly neutralizing …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human
immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …